Currently Viewing:
Newsroom
Currently Reading
Lack of Payer Support a Barrier to Diabetes Prevention, CDC Reports
December 17, 2017 – Mary Caffrey
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Average Profit Margin on Oncology Drugs For 340B Hospitals Nears 50%
December 15, 2017 – Jaime Rosenberg
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff

Study: CAR T-Cell Therapy Highly Effective in High-Risk Chronic Lymphocytic Leukemia

Kelly Davio
CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia who have failed to respond to treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor, according to a new study.
CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia (CLL) who have failed to respond to treatment with ibrutinib, a Bruton’s tyrosine kinase inhibitor, according to a study by Cameron J. Turtle, MD, and colleagues, newly published in the Journal of Clinical Oncology.

CLL is the most common leukemia in adults, and patients with CLL who have high-risk disease often have shorter survival. For patients who cannot tolerate aggressive chemotherapy, ibrutinib is often used, but complete response (CR) rate with this therapy is low, and some patients are intolerant to the treatment. CD19 CAR T-cell therapy shows promise for these patients; the recent, open-label phase 1 and 2 trial showed that CD19 CAR T cells induced durable remissions in some patients with CLL.

In the study, 24 patients with high-risk, relapsed or refractory CLL received lymphodepleting chemotherapy followed by an infusion of CD19 CAR T cells at 1 of 3 dose levels (2 x 105, 2 x 106, or 2 x 107 CAR T cells/kg). All of the patients had previously received ibrutinib; 19 had experienced progression while taking ibrutinib, and 3 were intolerant to the therapy. All of the patients discontinued ibrutinib before undergoing lymphodepletion, as the safety of concurrent CAR T-cell and ibrutinib therapy has not been established.  

The researchers found the following:
  • A majority of patients developed toxicities that are expected with lymphodepletion; 8 of the 24 patients developed neurotoxicity (1 patient developed fatal neurotoxicity).
  • The overall response rate 4 weeks after CAR T-cell infusion was 70% (16 of 23 restaged patients), and 1 additional patient achieved a later response.
  • Response rates were higher in patients who received CAR T cells after lymphodepletion with cyclophosphamide and fludarabine than in patients who underwent fludarabine-only lymphodepletion.
  • A lymph node response, which is associated with longer progression-free survival and OS, was achieved in 14 patients.
  • Of the 21 patients (all of whom had marrow disease before treatment) who underwent a marrow evaluation 4 weeks after CAR T-cell therapy, 17 (81%) had no detected marrow disease, and 15 of those 17 patients eliminated CLL from marrow.
  • 7 patients had no detectable malignant immunoglobulin heavy-chain locus sequences in their marrow 4 weeks after CAR T-cell therapy.
 

Six patients who had relapsed disease after 1 cycle of lymphodepletion and CAR T cells received a second cycle at either the same dose they had previously received (n = 1) or a 10-fold higher dose (n = 5). Among these patients, 2 achieved CR, and no residual CLL was detected.

The researchers noted that, while bone marrow disease was highly responsive to CAR T cells, bulky nodal disease was less responsive—a finding that suggests that the malignant lymph node environment may impair the CAR T-cell infiltration or function. The authors suggest that CAR T-cell therapy could be used while ibrutinib-induced mobilization of lymph node disease into blood or marrow is still effective in order to improve CR.

The authors concluded that CD19 CAR T-cell therapy is highly effective, with manageable toxicity, in high-risk CLL, including ibrutinib-refractory CLL, and that using this therapy can create sustained molecular remissions and improve prognosis.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!